文献速递免疫规划传染病防控与疫情报告

BBIBP-CorV疫苗接种加速异源奥密克戎感染者的抗病毒抗体应答:上海一项回顾性观察研究

BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
PubMed 文献 · Vaccine · 2023-04-19

本研究在上海招募440例奥密克戎感染患者,采用ELISA检测针对野生型和奥密克戎的SARS-CoV-2刺突蛋白受体结合域(RBD)及核蛋白抗体,分析BBIBP-CorV疫苗接种对异源奥密克戎感染后抗体应答的影响。结果显示接种者抗RBD IgG水平更高、抗体自发病即上升并于第8天达平台,重症仅见于未接种组。

要点

  • BBIBP-CorV接种者针对野生型和奥密克戎的抗RBD IgG水平在不同阶段均高于未接种者。
  • 接种者抗野生型和奥密克戎RBD IgG自发病即上升,第8天达平台;未接种者病程中保持低水平。
  • 重症COVID-19仅发生于未接种组。

核心结论

  • BBIBP-CorV疫苗接种有效降低奥密克戎感染者的疾病严重程度。
  • 通过BBIBP-CorV疫苗接种建立的体液免疫记忆应答有助于在遭遇SARS-CoV-2变异株感染时快速诱导回忆抗体应答。

研究设计与样本

  • 回顾性观察研究,在上海招募440例奥密克戎感染患者。
  • 采用ELISA检测针对野生型和奥密克戎的SARS-CoV-2刺突蛋白受体结合域(RBD)及核蛋白抗体,并分析临床相关性。

主要发现

  • BBIBP-CorV接种者针对野生型和奥密克戎的抗RBD IgG水平在不同阶段均高于未接种者。
  • 采用3天移动平均分析,接种者抗野生型和奥密克戎RBD IgG自发病即上升并于第8天达平台,而未接种者在病程中保持低水平。
  • 抗野生型RBD IgA仅在接种者中观察到显著升高;抗奥密克戎RBD IgA水平在接种者和未接种者中均保持低水平。
  • 重症COVID-19仅发生于未接种组。
  • 在接种者中,针对野生型和奥密克戎的抗RBD IgG和IgA与病毒载量、住院天数和病毒清除呈负相关。

关键数值与推荐

  • 接种者抗野生型和奥密克戎RBD IgG自发病即上升,第8天达平台;未接种者保持低水平。
  • 抗野生型RBD IgA仅在接种者中显著升高;抗奥密克戎RBD IgA在两组中均保持低水平。
  • 重症COVID-19仅发生于未接种组。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate how BBIBP-CorV vaccination affecting antibody responses upon heterologous Omicron infection. METHODS: 440 Omicron-infected patients were recruited in this study. Antibodies targeting SARS-CoV-2 spike protein receptor binding domain (RBD) and nucleoprotein of both wild-type (WT) and Omicron were detected by ELISA. The clinical relevance was further analyzed. RESULTS: BBIBP-CorV vaccinated patients exhibited higher anti-RBD IgG levels targeting both WT and Omicron than non-vaccinated patients at different stages. By using a 3-day moving average analysis, we found that BBIBP-CorV vaccinated patients exhibited the increases in both anti-WT and Omicron RBD IgG from the onset and reached the plateau at Day 8 whereas those in non-vaccinated patients remained low during the disease. Significant increase in anti-WT RBD IgA was observed only in vaccinated patients. anti-Omicron RBD IgA levels remained low in both vaccinated and non-vaccinated patients. Clinically, severe COVID-19 only occurred in non-vaccinated group. anti-RBD IgG and IgA targeting both WT and Omicron were negatively correlated with virus load, hospitalization days and virus elimination in vaccinated patients. CONCLUSIONS: BBIBP-CorV vaccination effectively reduces the severity of Omicron infected patients. The existence of humoral memory responses established through BBIBP-CorV vaccination facilitates to induce rapid recall antibody responses when encountering SARS-CoV-2 variant infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bao Y, He L, Miao B, et al. BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai. Vaccine. 2023. PMID: 37085449. doi:10.1016/j.vaccine.2023.03.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。